Top 50 Medical VC Funds & Investors in United Kingdom (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Scottish Enterprise
VC Fund
|
28 | United Kingdom, United States, Switzerland | Grant, Seed | Biotechnology, Software, Health Care | $119k–$4.3M |
|
Parkwalk Advisors
VC Fund
|
24 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.1M–$46M |
|
UK Innovation & Science Seed Fund
VC Fund
|
23 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $458k–$14M |
|
Oxford Science Enterprises
VC Fund
|
21 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
Deepbridge Capital
VC Fund
|
20 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
SFC Capital
VC Fund
|
17 | United Kingdom, United States, Canada | Pre-Seed, Seed | Artificial Intelligence, Software, Information Technology | $127k–$2M |
|
Archangels
VC Fund
|
17 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $1.3M–$8.3M |
|
Oxford Technology Management
VC Fund
|
15 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $33k–$7.9M |
|
SOSV
VC Fund
|
15 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Mercia Fund Managers
VC Fund
|
14 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $196k–$14M |
|
Northstar Ventures
VC Fund
|
14 | United Kingdom, United States, Indonesia | Seed, Series A | Software, Health Care, E-Commerce | $39k–$10M |
|
Scottish Investment Bank
VC Fund
|
14 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7M |
|
Cambridge Innovation Capital
VC Fund
|
12 | United Kingdom, United States, Ireland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$73M |
|
Empirical Ventures
VC Fund
|
12 | United Kingdom | Seed, Venture - Series Unknown, Pre-Seed | Medical, Biotechnology, Medical Device | $921k–$7.7M |
|
GM&C Life Sciences Fund
VC Fund
|
12 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
Development Bank of Wales
VC Fund
|
12 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$4.1M |
|
AlbionVC
VC Fund
|
11 | United Kingdom, United States, France | Series A, Seed | Software, Information Technology, Health Care | $2.2M–$20M |
|
Catapult Ventures
VC Fund
|
11 | United Kingdom, United States, Israel | Seed, Series A | Health Care, Biotechnology, Medical | $150k–$26M |
|
M Ventures
VC Fund
|
10 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Newable Private Investing
VC Fund
|
10 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.2M |
|
Innovate UK
VC Fund
|
10 | United Kingdom, United States, Ireland | Grant, Seed, Pre-Seed | Health Care, Biotechnology, Software | $58k–$3.7M |
|
Mercia Asset Management
VC Fund
|
10 | United Kingdom, United States | Series A, Seed | Software, Health Care, Information Technology | $1.1M–$13M |
|
Praetura Ventures
VC Fund
|
9 | United Kingdom, Germany, Ireland | Seed, Venture - Series Unknown | Software, Information Technology, Health Care | $393k–$10M |
|
Calculus Capital
VC Fund
|
9 | United Kingdom, United States, Ireland | Series A, Seed | Biotechnology, Software, Medical | $2M–$18M |
|
IP Group
VC Fund
|
9 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
Providence Investment Company Limited
VC Fund
|
8 | United Kingdom | Series B, Seed | Biotechnology, Biopharma, Medical | $1.9M–$24M |
|
Business Growth Fund
VC Fund
|
8 | United Kingdom, Ireland, United States | Venture - Series Unknown, Series A | Software, Information Technology, Health Care | $3.2M–$22M |
|
Oxford Capital
VC Fund
|
8 | United Kingdom, United States, France | Seed, Series A | Software, Health Care, Biotechnology | |
|
Foresight Group
VC Fund
|
8 | United Kingdom, United States, Ireland | Private Equity, Seed | Software, Manufacturing, Information Technology | $655k–$8.3M |
|
SyndicateRoom
VC Fund
|
8 | United Kingdom, United States, India | Seed, Equity Crowdfunding | Health Care, Software, Medical | $244k–$2.6M |
|
Wellcome Trust
VC Fund
|
8 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.6M–$127M |
|
Nesta Ventures
VC Fund
|
8 | United Kingdom, United States | Seed, Series A | Biotechnology, Medical Device, Medical | $982k–$26M |
|
Octopus Ventures
VC Fund
|
7 | United Kingdom, United States, Germany | Series A, Seed, Series B | Software, Health Care, Artificial Intelligence | $2.1M–$48M |
|
Forbion Capital Partners
VC Fund
|
7 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$176M |
|
Speedinvest
VC Fund
|
7 | United Kingdom, Germany, Austria | Seed, Series A, Pre-Seed | Software, FinTech, Financial Services | $549k–$33M |
|
Future Planet Capital
VC Fund
|
7 | United Kingdom, United States, Spain | Seed, Convertible Note | Biotechnology, Health Care, Software | $670k–$7.3M |
|
Salica
VC Fund
|
7 | United Kingdom, United States, Germany | Seed, Series A, Secondary Market | Software, Information Technology, Health Care | $700k–$21M |
|
SIS Ventures
VC Fund
|
7 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1.1M–$19M |
|
QUBIS
VC Fund
|
6 | United Kingdom, United States | Seed, Grant | Health Care, Medical, Biotechnology | $604k–$2.8M |
|
Oxford Investment Consultants LLP
VC Fund
|
6 | United Kingdom | Series A, Seed | Software, Health Care, Biotechnology | $982k–$33M |
|
Playfair Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, E-Commerce | $700k–$20M |
|
Nina Capital
VC Fund
|
6 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$21M |
|
Abingworth
VC Fund
|
6 | United States, United Kingdom, France | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $14M–$120M |
|
Crista Galli Ventures
VC Fund
|
6 | United Kingdom, United States, Sweden | Seed, Pre-Seed, Series A | Health Care, Medical, Wellness | $655k–$14M |
|
Epidarex Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $531k–$55M |
|
Tern
VC Fund
|
6 | United Kingdom, United States | Seed, Convertible Note | Software, Information Technology, Medical | $364k–$1.4M |
|
Syncona Partners LLP
VC Fund
|
6 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.8M–$170M |
|
Kindred Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1.5M–$73M |
|
Eos
VC Fund
|
6 | United Kingdom, Ireland, United States | Seed, Series A | Biotechnology, Health Care, Medical | $1.4M–$47M |
|
VentureFounders
VC Fund
|
5 | United Kingdom, United States | Series A, Series B | Health Care, Medical, Software | $643k–$25M |
| Access all 1133 VC funds in United Kingdom Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 360
- Round size: Seed $375k–$3.9M; Grant $119k–$4.3M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
- Trojan Energy — Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.
- Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 277
- Round size: Seed $1.1M–$5M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
- Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
- PredictImmune — Pragmatic play menciptakan demo slot x500 yang merupakan slot online gratis. Nikmati slot demo pragmatic gacor gampang menang di demo pragmatic jamin gacor.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 135
- Round size: Seed $458k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Hexigone Inhibitors — Hexigone aims to replace toxic chemicals used in the anti-corrosion market with our disruptive, novel, micro/nano reservoir technologies, creating 'smart' coatings. Our additives will enable the coatings to protect for longer in an intelligent manner, increasing the lifetime cycle of the end product, reducing the drain on primaryresources.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 178
- Round size: Seed $1.3M–$12M; Series A $6.3M–$49M; Series B $13M–$168M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- AlveoGene — Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- Caudal Energy — Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 86
- Round size: Seed $152k–$2.6M; Series A $2M–$15M
- Lead/follow: 72% lead, 28% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- HeadBox — HeadBox connects corporate event planners with 100,000+ unique, inspiring, iconic, and creative spaces worldwide for meetings and events.
- Touch Biometrix — Welcome at Touch Biometrix. Find out more about The Future of Fingerprint Biometrics!
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Pre-Seed, Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 488
- Round size: Seed $127k–$2M; Pre-Seed $164k–$839k
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $1.9M in 2019
Portfolio highlights
- Sages — Biodegradeable, non-polluting, low-impact and vibrant dyes extracted from food waste.
- Traknova — Traknova provides an AI-powered fleet management platform that helps companies track, manage, and protect vehicles and mobile assets. The platform offers real-time GPS tracking, live monitoring, and telematics data to give operators constant visibility over fleet movements and status. Users can access an intuitive dashboard with historical tripinformation, engine status, and alerts for events such as geofence breaches or unauthorized use. Traknova also supports integrated hardware, including tracking devices and online cameras, to strengthen asset security and streamline recovery when issues arise. The system is designed for fleets across industries, such as service businesses and vehicle rental operators, that need clearer scheduling, better time management, and improved operational control. By consolidating these tools into one platform, Traknova enables data-led fleet planning and day-to-day decision-making.
- GNOSIS Health — Gnosis Health is a digital healthcare platform specializing in artificial intelligence and wearable technology for chronic disease management.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 85
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Bioliberty — Engineering the future of physical and occupational therapy.
- Earth Blox — Earth Blox is a paradigm shift for teaching Earth observation skills to everyone from children to university students & professionals.
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 109
- Round size: Seed $33k–$2.1M; Series A $786k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
- Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 136
- Round size: Seed $196k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Sen — Sen's vision is to democratize space using video to inform, educate, inspire and benefit all humanity. Sen's mission is to stream real-time videos from space to billions of people, gathering news and information about Earth and space and making it universally accessible.
- Gentronix — Gentronix is a contract research organisation (CRO) providing a wide range of screening and safety services, including genetic toxicology screening and regulatory genotoxicity studies.
- Haystack — Giving techies the tools to uncover, explore and discover the tech landscape with full anonymity - showcasing opportunities that match their interests, values and tech stack.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 199
- Round size: Seed $39k–$2.2M; Series A $851k–$10M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
- NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
- MySalesCoach — MySalesCoach offers Despite overwhelming evidence that sales coaching has the greatest impact on rep development and success, managers typically devote less than 5% of their time to coaching a team that craves and deserves coaching to reach their full potential.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 208
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 101
- Round size: Seed $2.5M–$31M; Series A $2M–$73M; Series B $8.5M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
- Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
- TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Empirical Ventures supports innovative approaches to critical problems in the fields of biotechnology and life sciences.
Show more...Investment focus
- Industry: Medical, Biotechnology, Medical Device
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 31
- Round size: Seed $921k–$5.1M; Pre-Seed $1.1M–$1.6M; Venture - Series Unknown $2.3M–$7.7M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Fermtech — Fermtech provides equipment for precision fermentation companies to scale production processes. Fermtech was founded in 2022 and was headquartered in Oxford, England.
- Orthofuse — Orthofuse is a medtech company that provides orthopaedic solutions using 3D-printed implant systems designed to improve the safety and efficiency of surgical procedures.
- Caudal Energy — Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics.
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 237
- Round size: Seed $360k–$3.3M; Debt Financing $18k–$4.1M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- IQ Endoscopes — Fully Disposable Endoscopes for General Medical Use. A successful initial investment funding round completed, we are seeking future funding to take the IQ Scope to market.
- MeOmics Technology — MeOmics Technology is a biotech company with a focus on improving the diagnosis and treatment of mental health illnesses. The company operates in the manufacturing industry and has a team of 9 employees. The team includes experts in Neuronal Cell Biology and Neuropsychopharmacology. The company's mission is to leverage technology to enhancethe understanding and treatment of mental health conditions.
- Bond Digital Health — Bond Digital Health is a technology company developing end-to-end digital connectivity for the point-of-care diagnostics market. Developed by founders Ian Bond and Dave Taylor and originally designed as a patient self-management tool, Bond’s digital technology was remodeled to meet the needs of a client - a world-renowned innovator in point-of-carediagnostics and the lateral flow industry. The client required a digital platform consisting of a patient-facing mobile app and cloud data management for their new quantitative diagnostic test for chronic lung disease. They shared their experiences of working with us with a collaborator company who quickly commissioned Bond to develop a similar product for chronic wound care. Others in the lateral flow industry recognised that an affordable, compliant and scalable solution was available highlighting a huge unmet need in an expanding market. Bond is working in strategic partnerships with key industry leaders to create the next generation of digitally connected lateral flow diagnostics that provide an elevated user experience and enhanced real-time decision-making through the power of data aggregation and data analytics.Our regulatory strategy ensures that the solutions we create are secure, reliable and compliant with regulatory standards, making us a trusted partner to leaders in human health, animal health and agri-food globally.In Bond Digital Health we believe that collaborative working is the only way to tackle some of the major health challenges the world is nowadays facing. Our technology brings the life sciences industry closer together to create solutions that improve the lives of millions.Let’s make a difference together!
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 168
- Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Umedeor — uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams
- Xperiome — Match research-ready members to clinical and real-world studies, faster and smarter than ever before through data-driven insights into the rare disease experience.
- Hussle — Gym membership with total flexibility. Gym passes to no contract gym memberships that you can use in thousands of gyms across the UK. Gym and swim wherever you want to. Stop and start whenever you like.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 105
- Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 171
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $196k–$3.9M; Series A $1.3M–$5.2M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
- NuVision — NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Innovate UK is part of the UK Research and Innovation .
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Grant, Seed, Pre-Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 759
- Round size: Seed $367k–$3.7M; Grant $62k–$1.8M; Pre-Seed $58k–$1.5M
- Lead/follow: 82% lead, 18% follow
Portfolio highlights
- Paranimo — Nuvra is a responsive Webflow template for healthcare startups. Customizable, fast, and SEO-optimized to elevate your brand.
- Greener — Greener uses maths to make it easy for businesses to discover, connect, and collaborate with perfectly suited sustainability partners
- Open Data Institute — The Open Data Institute will catalyse the evolution of an open data culture to create economic, environmental, and social value. It will unlock supply, generate demand, create and disseminate knowledge to address local and global issues.The Open Data Institute will convene world-class experts to collaborate, incubate, nurture and mentor newideas, and promote innovation. We will enable anyone to learn and engage with open data, and empower our teams to help others through professional coaching and mentoring.Founded by Sir Tim Berners-Lee and Professor Nigel Shadbolt, the ODI is an independent, non-profit, non-partisan, limited by guarantee company.The ODI has secured £10 million over five years from the UK Government (via the UK innovation agency, the Technology Strategy Board), and $750,000 from Omidyar Network, and is working towards long-term sustainability through match funding and direct revenue.With a 5,000 sq ft convening space based in the heart of London's thriving Shoreditch area, and a global remit, we invite everyone intrested in developing Open Data to get in touch.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 65
- Round size: Seed $1.1M–$3.1M; Series A $4.8M–$13M
- Lead/follow: 65% lead, 35% follow
Portfolio highlights
- Netacea — Netacea takes a smarter approach to bot management. Intent Analytics™ powered by machine learning quickly and accurately distinguishes bots from humans to protect websites, mobile apps and APIs from automated threats while prioritising genuine users. Actionable intelligence with data-rich visualisations empowers you to make informed decisions aboutyour traffic. The Netacea approach offers incredible speed, accuracy and transparency, solving the growing problem of credential stuffing and account takeover at scale. The technology is designed to complement existing controls such as WAF rulesets, rate limiting and threat databases to provide a deep analysis of all website visitors, actionable intelligence and real-time threat.The Netacea approach continuously monitors your web traffic to pinpoint the difference in automated bot activity vs genuine visitors, keeping you ahead of evolving bot threats. Choose to automatically block, redirect or challenge automated attacks in real-time, or receive alerts notifying you of potential threats. With access to rich dashboards and data, you can easily identify and stop account takeover attempts early in the attack chain.Learn more at www.netacea.com
- Semble — The integrated clinical system for managing your patients' medical data and admin tasks.
- Camena Bioscience — Camena Bioscience is a synthetic biology company that develops tools to engineer new synthetic biology applications. It has engineered new nucleic acid synthesis technology which improves the quality and speed of synthesis. Its multi-enzymatic technology takes one approach to DNA, RNA, and XNA synthesis, offering increased accuracy over existingPhosphoramidite synthesis technology.Camena Bioscience was founded in 2016 and is headquartered in Cambridge.
Praetura Ventures has been supporting entrepreneurs with more than money since 2011. Click to find out more about how we can help businesses and investors.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom, Germany, Ireland
Investor stats
- Total investments: 143
- Round size: Seed $393k–$5M; Venture - Series Unknown $445k–$10M
- Lead/follow: 77% lead, 23% follow
Portfolio highlights
- We Influence — We Influence is a digital marketing agency specializing in search marketing and conversion rate optimization. The company also specializes in PPC, SEO, affiliate, social media, and content marketing, working with eCommerce brands across the UK to help catapult them to the next level of their growth. They help reach more potential customers throughsocial media channels to boost profitability and brand reach.We Influence transforms their clients’ businesses by catapulting them to the next level of their e-commerce growth.
- Culture Shift — Culture Shift can help you transform your organisation by seeing and responding to culture-damaging behaviours. Hear your people when it matters most.
- Patchwork — NHS workforce solution for managing rotas, bank shifts, and staffing. Trusted by 200+ organisations. Built by healthcare professionals.
At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.
Show more...Investment focus
- Industry: Biotechnology, Software, Medical
- Stage:Series A, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 74
- Round size: Seed $2M–$18M; Series A $3.3M–$10M
- Lead/follow: 66% lead, 34% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Trogenix — Trogenix operates as a therapeutics company, that treats aggressive cancers.
- Grateful — Grateful provides cashless tipping and trunk management software that integrates QR/NFC, EPOS systems, and compliance reporting.
- Resurrect Bio — Resurrect Bio is a disease resistance trait discovery company. Using AI and our high-throughput in planta screening platform we provide traits for breeders.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 193
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Barocal — Barocal is a Zero-carbon refrigeration pioneer.
- Slamcore — Positioning, mapping and perception | State-of-the-art visual SLAM turns sensor data into actionable, spatial understanding for your vehicles.
- Kynos Therapeutics — Leading an inflammation revolution
Providence Investment Company
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Medical
- Stage:Series B, Seed
- Geography: United Kingdom
Investor stats
- Total investments: 13
- Round size: Series B $1.9M–$24M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- evonetix — evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
- DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
- Cambridge Photon Technology — Cambridge Photon Technology is a developer of organic photovoltaic devices used to enhance next-generation solar technology. Its devices engage in the deployment of off-grid solar power and use advanced nanotechnology to split each incoming blue and green photon into two infra-red photons that enable clients to deploy solar power throughlightweight devices whenever needed.
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Venture - Series Unknown, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 354
- Round size: Series A $3.2M–$21M; Venture - Series Unknown $4.4M–$22M
- Lead/follow: 83% lead, 17% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Antser — Antser provides business support services, technology solutions, and training and development to the care sector.
- Gymbox — Making sweating enjoyable drives everything Gymbox does. From our unique exercise classes and nightly resident DJs, through to our larger than life personal trainers, at Gymbox there is undeniably a culture of fun.
- OCL Vision — Expert eye care from trusted UK specialists. From laser vision correction to cataract surgery, discover life-changing treatments.
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 141
- Lead/follow: no public data
Portfolio highlights
- Egregious — Egregious is an advanced research & intelligence lab established to defend humans from AI and provides narrative intelligence solutions across the public and private sectors to protect organisations and online users from malign influence using AI-driven data acquisition, insights, and engagement.
- Arcube — We make sure all travellers, frequent and infrequent, make the most of travel loyalty programs, using our data-driven approach, airlines can understand their customers and provide hyper-personalised offerings to boost value and retention.Arcube uses a data-driven approach to make the most of airline loyalty programs for both frequent andinfrequent flyers. Our software allows airlines to understand their customers and provide hyper-personalised offerings to boost value and retention at no extra cost to the airline.
- FinCrime Dynamics — Our mission is to help make the world’s financial system safer through rapid deployment of effective AI for financial crime analytics, enabled by enriched synthetic data that captures the dynamics of fraud and money laundering and loads them into tailor-made scenarios that explore diverse threats that financial organisations are exposed to.Thisgoal has taken us to the forefront of Synthetic Data and Fincrime Analytics, and we are proud to have in our team people that have helped shape the state-of-the-art of these fields.Keywords: Finacial services, AML, Synthetic Data, Fintech, Machine learning, Big data, Simulation, Fraud Analytics, Compliance
Foresight Group is a listed infrastructure and private equity investment manager which has been managing funds on behalf of institutions and retail clients for more than 35 years. Foresight has over £7.2 billion of assets under management across a number of funds on behalf of some of the world’s largest institutional investors, family offices,private and high net-worth individuals and retail investors. Foresight's investment strategies are underpinned by a strong environmental, social & governance (“ESG”) focus, which increasingly meets the demands of today’s investors and ensures we are consistently working towards creating a sustainable legacy for future generations.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Private Equity, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 199
- Round size: Seed $655k–$7.3M; Private Equity $2.1M–$8.3M
- Lead/follow: 65% lead, 35% follow
Portfolio highlights
- iMist — iMist water mist fire suppression systems are perfect for commercial, industrial and residential applications. More effective, uses less water, and is more economical than traditional fire sprinkler systems.
- usheru — usheru is an innovation-driven company in the film and entertainment industries, focused on marketing and analytics solutions.
- Industrial Engineering Plastics — Industrial Engineering Plastics delivers specialist thermoplastic fabrication for demanding industrial applications.
SyndicateRoom is fintech company made up of data-scientists, investment professionals, software developers and marketers with one mission: to be an early investor in every British startup success story.To do this – and make fund investors money – we don’t try to spot the next Big Thing.Instead, we apply a data-driven model to portfolioconstruction; a repeatable process designed to maximise returns and minimise risk for fund investors. As such, we build startup portfolios that don’t attempt to predict the future; they work to stack the odds in investors’ favour.Our fund, Access EIS, aims to build investors a diversified portfolio of 50+ companies by co‑investing exclusively with some of the UK’s best-performing angel investors.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Seed, Equity Crowdfunding
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 139
- Round size: Seed $360k–$2.6M; Equity Crowdfunding $244k–$1.6M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- ManaMind — ManaMind is an AI-powered platform that automates video game quality assurance (QA) testing using autonomous bots to help developers identify bugs faster and cheaper.
- Xperiome — Match research-ready members to clinical and real-world studies, faster and smarter than ever before through data-driven insights into the rare disease experience.
- Joyvié — Joyvié Health designs medical continence products focused on managing severe faecal incontinence. The company is developing a patent-pending class of non-invasive faecal management briefs that prevent stool from contacting the skin. By separating waste from the body, the underwear aims to lower the risk of skin breakdown and secondary infectionwhile reducing the physical and emotional strain on caregivers. Joyvié Health works with care providers to pilot its products in real-world care environments and gather clinical and user feedback. Its offering is intended for adults with continence needs in institutional and home care settings, and for professionals responsible for continence care. The company also engages with investors and partners to advance product development and clinical evaluation.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 124
- Round size: Grant $1.6M–$10M; Series C $10M–$127M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Wysa — Use Wysa to vent or just talk through negative thoughts and emotions. Let it help you cope with pandemic anxiety and lockdowns. It is anonymous, safe and free.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
We bring bold ideas to life to change the world for good.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 72
- Round size: Seed $982k–$2.2M; Series A $1.5M–$26M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $34M in 2014
Portfolio highlights
- Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
- Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
- Radio Physics Solutions — PASAR123 merupakan landasan utama bandar slot nomor 1 di indonesia memiliki fasilitas slot deposit pulsa tanpa potongan penarikan sangat mudah dan cepat.
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 387
- Round size: Seed $2.1M–$13M; Series A $3.2M–$21M; Series B $7.5M–$48M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $101M in 2019
Portfolio highlights
- Turtl — Create personalized interactive content experiences that excite, engage and convert your audience with Turtl's intuitive content software.
- Sprout.ai —
- Minimum — Take control of your organization's carbon accounting and management with granular, robust and auditable emissions data.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 200
- Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Speedinvest is a globally active European venture capital firm built on a simple belief: many move more. From six offices across EMEA, our sector-focused investment teams back relentless founders from pre–Seed to Growth with long-term conviction, providing day-one access to our global network of corporate customers, experts, industry leaders, andtop-tier follow-on investors to scale smarter and faster. Building lasting companies like Bitpanda (Austria), Moove (Nigeria), Gigs (U.S.), Tide (UK), ARX Robotics (Germany), Wayflyer (Ireland), GoStudent (Austria), Seqera Labs (Spain), and Cylib (Germany) — together. Big ideas may start with one. But scaling and winning take The Power of More.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, Germany, Austria
Investor stats
- Total investments: 552
- Round size: Seed $980k–$8M; Pre-Seed $549k–$4.1M; Series A $4M–$33M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $384M in 2022
Portfolio highlights
- Bikemap — Bikemap is the crowdsourced cycling map & navigation of the world. With the help of more than 2.3M users in 100 countries, Bikemap helps you find the best cycling route from A to B - every time. Users shared more than 4M cycling routes in all corners of the world - and within the Bikemap Premium subscription, tens of thousands get access tooffline, routing, map features.
- morgana — Morgana is reshaping the mortgage industry in Latam. With a 5x faster application process, in-depth market knowledge, privileged access to data, and superb team, we are a groundbreaking digital mortgage broker that will shortly be competing with banks.
- GAMINSIDE — GAMINSIDE revolutionizes your relationship with your customers. As European full service provider, we deliver the complete package with solutions, services and software for gamified loyalty that is tailor-made and unique to your products, brands and customers. Integrate the best ideas from gamification and customer loyalty in your business areato exceed your commercial targets with GAMINSIDE.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 169
- Round size: Seed $670k–$7.3M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Unloq AI — Unloq AI creates embedded, co-created technologies that link your business objectives to actual AI-enabled execution.
- Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
- NeoVac — NeoVac is creating revolutionary, unique and proprietary next-generation lipid nanoparticles to enable better RNA vaccines and treatments for various diseases.
Founded as an investment firm focusing on the most promising startups, we have evolved into a unique set of private market funds investing globally in equity and debt across complementary sectors and stages. We fuse traditional values with a contemporary approach and balance exacting processes with the agility to capture commercial opportunity andcompelling investment returns. Our continuous search for new opportunities has led us to create a balanced collection of complementary funds and relationships.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A, Secondary Market
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 204
- Round size: Seed $700k–$5M; Series A $5M–$21M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- CameraMatics — Digitize fleet management to optimize performance. Onboard sensors, smart cameras, & apps to mitigate risk, manage safety & achieve sustainability goals.
- Modern Milkman — Modern Milkman is a Yorkshire-based milk delivery company.
- SURI (Sustainable Rituals) — A world-class clean that doesn’t cost our planet. SURI is the new, sustainable electric toothbrush. Delivering an effective clean with innovative plant-based materials.
SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 33
- Round size: Seed $1.1M–$4.9M; Series A $2.8M–$19M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $1M in 2018
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Trojan Energy — Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.
Working with academic entrepreneurs, QUBIS Ltd has grown a portfolio of shareholdings in viable companies over 27 years that have succeeded on an international level.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Grant
- Geography: United Kingdom, United States
Investor stats
- Total investments: 31
- Round size: Seed $604k–$2.8M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- StimOxyGen — StimOxyGen specializes in developing innovative, pH-responsive nanoparticles designed to generate oxygen in hypoxic tumors. This technology aims to enhance the effectiveness of cancer treatments such as radiotherapy and chemotherapy by addressing tumor hypoxia, a significant clinical challenge. F
- Cibus Analytical — Cibus Analytical operates as a food testing specialist. Cibus Analytical offer a laboratory testing service for food authenticity and safety, as well as extend its product offering to include portable testing tools to allow customers to rapidly test for food authenticity and safety at the point of sampling across global supply chains.
- Porous Liquid Technologies —
xford Investment Consultants LLP ("OIC") advises Thompson Taraz, the Investment Manager of Oxford Technology and Innovations EIS Fund ("OTIF"). OIC is an Appointed Representative of Stoneware Captial LLP, which is authorized and regulated by the Financial Conduct Authority in the United Kingdom.The focus of OIC research ison University of Oxford spin out companies.Over the last fifteen years Oxford has produced a string of world-class spin-out companies. It is our belief that the next generation of world-class Oxford businesses is just waiting to be discovered.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Seed
- Geography: United Kingdom
Investor stats
- Total investments: 27
- Round size: Seed $982k–$7.6M; Series A $8M–$33M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Diffblue — Diffblue Testing Agent generates, verifies, and fixes unit tests autonomously across enterprise codebases.
- Panda Surgical — Panda Surgical is developing a next-generation handheld robotics platform that offers neurosurgeons enhanced dexterity and control in confined spaces, enabling more surgeons to perform complex minimally invasive procedures.
- Oxford Quantum Circuits — Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Playfair is a sector agnostic fund focused exclusively on pre-seed investing. Based in London, Playfair invests across the UK and Europe with an intentionally high conviction, low volume approach: making six investments a year out of its third $70m fund and preserving time, capital and resource to help companies post-investment. Our 78% Series Agraduation rate is ~3x industry average. Playfair has backed 100+ companies since 2013, including Thought Machine, Orca AI, Protex AI, StackOne and Nory.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, E-Commerce
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 139
- Round size: Seed $1M–$7.6M; Pre-Seed $700k–$3.1M; Series A $2.7M–$20M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Wassist — Wassist is a platform for building AI-powered WhatsApp agents that help businesses automate sales, customer support, and marketing directly inside WhatsApp.
- Astral Systems — Our compact multi-state fusion reactors offer high particle flux and exceptional lifetime performance, unlocking a wide variety of critical medical, industrial, and research applications today.
- Passionfruit — Join hundreds of the best startups around the world and use Passionfruit to hire freelance marketing specialists on-demand.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 89
- Round size: Seed $2M–$6.3M; Pre-Seed $573k–$2.4M; Series A $5M–$21M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Navidence — Navidence provides a transformative Real World Evidence (RWE) Design platform that enables organizations to efficiently adapt to the ever-increasing ecosystem of Real World Data (RWD) sources. The company unlocks the power of Computable Operational Definitions (CODefs) for RWE Design and RWD Assessment. Navidence's RWE Sherpa platform offerstools to streamline the process of defining an RWE study's data, making it easier for researchers to conduct their studies in the age of data.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Ladder Health — Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.
We are Abingworth, a trans-atlantic bio-science investment firm with a deep understanding of both the science and markets we invest in.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 173
- Round size: Series A $14M–$115M; Series B $18M–$95M; Series C $20M–$120M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $356M in 2023
Portfolio highlights
- Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
- Iambic — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
- Addition Therapeutics — Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies.
Physician-led venture capital investing in TechBio, DeepTech Healthcare, and Digital Health.
Show more...Investment focus
- Industry: Health Care, Medical, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Sweden
Investor stats
- Total investments: 36
- Round size: Seed $960k–$8.5M; Pre-Seed $655k–$2.5M; Series A $5.2M–$14M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Jude — Science-backed food supplement that makes you feel empowered, not embarrassed.
- Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
- Collective Minds — Collective Minds develops and delivers a cloud-based collaboration platform for healthcare and research with access to data, human and digital expertise.
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 48
- Round size: Seed $531k–$8.5M; Series A $2.6M–$38M; Series B $2.4M–$55M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
- Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Looking for an IoT investor for your start up or early stage company? Tern PLC is a venture capitalist working alongside ambitious entrepreneurs in the Internet of Things (IoT) space to deliver strategic IoT investment to grow your company.
Show more...Investment focus
- Industry: Software, Information Technology, Medical
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States
Investor stats
- Total investments: 21
- Round size: Seed $1.2M–$1.4M; Convertible Note $364k–$917k
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Konektio — Konektio is a dedicated M2M and IoT company which uses the best technology to deliver performance and solutions quickly and cost effectively. When you enquire we will need to visit you to discuss how to maximise the Konektio benefits for your particular business, whether OEM or End User, and also the type of devices (things) that you wish toconnect to. Our experience will help you to get the most out of any investment.
- FundamentalVR — Solutions for knowledge acquisition and skills development for any interactive medium
- Talking Medicines — Data Science for Life Sciences. Talking Medicines turns unstructured health data into actionable intelligence that proves real marketing impact.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 62
- Round size: Seed $1.8M–$17M; Series A $17M–$110M; Series B $24M–$170M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- Apini Therapeutics — Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Re-Aim Therapeutics — Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 112
- Round size: Seed $1.5M–$16M; Series A $7.9M–$35M; Series B $13M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Paddle — The revenue engine powering payments for n8n, Letterboxd & AdGuard. One platform that handles subscription billing, payments and compliance.
- how.fm — Training software for better onboarding processes and digital store floor management. Train staff with no effort and language barriers.
- Scarlet — Continuous compliance
Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving lives.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 42
- Round size: Seed $1.4M–$11M; Series A $1.6M–$47M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- Nami Surgical — Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments.
- Cumulus Oncology — Cumulus Oncology develops anti-cancer therapies for clinical settings in areas of high unmet need. We target key pathways to improve the efficacy and outcomes of current and experimental therapies. Cumulus has the backing of a successful entrepreneur in the oncology field and is led by a team of senior professionals and industry partners fromacross the drug discovery and development sector. Together, we offer a wealth of experience and deep insights into optimum approaches for improved cancer patient outcomes.
Volution is a UK based Venture Capital firm. We back ambitious Fintech and SaaS businesses, ready to accelerate their growth to Series B and beyond.
Show more...Investment focus
- Industry: Health Care, Medical, Software
- Stage:Series A, Series B
- Geography: United Kingdom, United States
Investor stats
- Total investments: 51
- Round size: Series A $643k–$9.8M; Series B $4.3M–$25M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Zopa — Zopa is a P2P money lending service that allows lenders and borrowers to deal directly with one another, cutting out the banks who act as middlemen. It works in the following way: the company first categorizes borrower credit grades with an A*, A, B, C, or Y rating; then lenders make offers that vary by money amount and time period for persons witha certain credit grade, and borrowers can then agree the aggregate offered rate.Zopa takes on such responsibilities as distributing money between parties, completing the legal paperwork, performing borrower identity/credit checks, and employing a collections agency that chases missed payments for the lender.Zopa also mitigates risk for lenders by enforcing monthly direct debit repayment, making borrowers sign a legal contract, and allowing lenders to lend small chunks of money to individual borrowers (i.e. someone lending £1000 would have their money spread across say, 100 borrowers).The company itself makes money by charging a fixed fee for borrowers and a 1% annual fee for lenders.Zopa has received public acclaim as well, having been awarded CNET Technology Awards' 2006 Internet Innovation of the Year, the 2007 Webby Award for Best Banking/Bill-Paying Website, the 2008 Webby Award for Financial Services, the Banker 2007 Award for Best Internet Project, and Moneywise 2009 Awards for Best Customer Service and Best Personal Loan.One of the three initial members of the UK's Peer-to-Peer Finance Association, together with FundingCircle and RateSetter. Other P2P lending services include
- DeadHappy — DeadHappy is an insurtech company that provides digital pay-as-you-go life insurance services. It specializes in offering flexible life insurance policies that are designed to be cheaper, easier, and better than existing traditional providers. Its offerings include pricing insurance based on current circumstances and the option to add furthercoverage on a rolling basis.The company was founded in 2013 and is headquartered in Leicester, England.
- Lightpoint Medical — Miniature, drop-in gamma probe system for minimally-invasive, robot-assisted cancer surgery.
Medical VC funding in United Kingdom at a glance
Stats across 1.4k deals from 1.1k investors.
Access all 1133 VC funds in United Kingdom Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1133 VC funds investing in United Kingdom Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!